EBOLA UPDATE

BOARD MEETING
Aurélia Nguyen, Stefano Malvolti
10-11 JUNE 2015, Geneva
Feedback from PPC & WHO Ebola summit

Feedback from Programme and Policy Committee (4-6 May 2015):

• PPC endorsed need for country-tailored support to restoring immunisation programmes and strengthening health systems
• PPC acknowledged need to further discuss role of Gavi in future preparedness to health emergencies

Feedback from WHO R&D Ebola summit (11-12 May 2015):

• Lessons learnt from Ebola epidemic should guide R&D efforts to ensure improved preparedness to future emergencies
• Gavi highlighted need to optimise or expedite development of life-saving vaccines and ensure supply thereof in sufficient quantities
• WHO to develop framework for efficient, collaborative research and information sharing across different players
In accordance to Board decision, Gavi’s support for Ebola spans along 4 dimensions:

1. Production & Procurement funding: US$ 300M
2. Funding vaccine roll-out: US$ 45M
3. Future outbreak preparedness (stockpiling)
4. Recovery of health and immunisation systems: US$ 45M
Evolution Ebola epidemics in Sierra Leone and Guinea as per June 10th

- >27,100 cases; >11,150 deaths (> 500 health workers)

- 31 confirmed cases in Guinea (16) and Sierra Leone (15) combined: Notable increase in comparison with 25 cases the previous week

- Liberia: declared free of Ebola on May 9th; state of heightened vigilance maintained till end of June

- Several cases from unknown sources indicating that chains of transmission continue to go undetected

- Community engagement & surveillance strategies to be further improved to prevent unsafe burials and make contact tracing more effective

- Upcoming rainy season poses challenge to field operations

Source: WHO Ebola Situation report; 10 June 2015
Procurement strategy and support to manufacturers to be shaped depending on evolving perspectives for vaccine development and approval.

**Ebola vaccine:**
- At risk populations
- Stockpiling (incl. 2nd generation)

**Possible Funding**

**Q4 2015/Q1 2016**

**Preclinical with EOI**
- 7

**PhI**
- 5

**PhII**
- 2

**PhIII (Guinea + Sierra Leone)**
- 1 (rVSV)

**Approval WHO recommendation**

**Procurement**
Investment and procurement of Ebola vaccines: A delicate balancing act between conflicting goals

- Preparedness for unknown evolution of the epidemics
- Availability of supply for products of unknown development/regulatory outcome
- Responsible stewardship of funds
Activities ongoing in countries to address outbreaks of VPDs and remedy shortcomings in immunisation systems

- 2014 coverage: 61% DTP3 and 56% MCV1
- Measles outbreak in 10 counties
- Pertussis outbreak in 1 county
- Dec 2014: 1st first round of PIRI across various antigens
- Feb 2015: 2nd round of PIRI
- May 2015: Polio SIA and Measles ORI 9-59m

- 2014 coverage: 54% DTP3 and 56% MCV1
- Measles outbreak in 5 districts
- MenA outbreak (16 deaths)
- Q1: Measles ORI in 2 districts
- April 2015: 2nd ORI (6m-10y) in 10 districts
- May ’15: MenA mass campaign
- October ‘15: National Measles SIA (9-59m)

- 2014 coverage: 93% DTP3 and 89% MCV1 (admin data)
- Measles outbreak in 6 provinces (142 cases/2 deaths as per Feb)
- April 2015: Polio SIA
- May 2015: Polio & measles ORI (9-59m) with multi-intervention campaign (Mother Child Health Week)

Country-tailored support to health systems recovery and strengthening in coordination with partners (World Bank and BMGF)